A trusted and essential partner
to the biopharmaceutical
industry, providing 27 years
of in-depth research, analysis
and data on innovation
and excellence —
from biology to the patient.

Get a Free Trial

7:20 PM Feb 15, 2019
BioCentury  |  Product Development

ADCs’ inflection point

Industry is writing a new rule book for antibody-drug conjugates that could take the modality beyond the one-size-fits-all approach that has limited its success. By 2Q20, late-stage data from at...

Read More
4:45 PM Feb 15, 2019
BioCentury  |  Product Development

Embedding digital in Lilly’s portfolio

In its newly created position of chief digital officer, Eli Lilly and Co. is avoiding the rush to an all-out, all-encompassing role, instead circumscribing the focus to tools that improve patient...

Read More
7:03 PM Feb 14, 2019
BC Innovations  |  Tools & Techniques

Heartening predictors in diabetes

New biomarkers of cardiovascular risk could relieve a decade-old bottleneck for diabetes drug development, but validating them will require companies to invest in strategic trial designs, and...

Read More
4:23 PM Feb 14, 2019
BC Innovations  |  Product R&D

A bug about Alzheimer’s

Cortexyme Inc. believes it has connected the dots between Alzheimer’s and gum disease, outlining a path from the bacteria that cause periodontitis to chronic brain infection with hallmarks of...

Read More
5:54 AM Feb 14, 2019
BioCentury  |  Finance

HKEX: where East meets West

Unfazed by the shaky start of the Hong Kong stock exchange’s new biotech chapter, HKEX CEO Charles Li thinks its position at the nexus of East and West will underpin its long-term success. With...

Read More
1
2
3
4
5

Browse

{{ item.title }}
Browse all categories